Craig C. Parker - 24 Mar 2025 Form 4 Insider Report for Surrozen, Inc./DE (SRZN)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: SRZN
Reported as of: 24 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Mar 2025, 21:33:12 UTC
Prior SEC filing: 22 Jan 2025
Next SEC filing: 05 May 2025
Source filing: View source filing
Reporting owner signature: /s/Charles Williams, Attorney-in-Fact for Craig C Parker

Key filing fact

Craig C. Parker filed Form 4 for Surrozen, Inc./DE (SRZN) on 25 Mar 2025.

Key facts

This page summarizes Craig C. Parker's Form 4 filing for Surrozen, Inc./DE (SRZN).
6 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 25 Mar 2025, 21:33.

Change

Previous filing in this sequence was filed on 22 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SRZN transaction Derivative

Series A Common Stock Warrant (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -1,474
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 24 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,474
Exercise price: $16.96
Footnotes: F1

SRZN transaction Derivative

Series B Common Stock Warrant (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -1,603
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 24 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,603
Exercise price: $15.71
Footnotes: F2, F3

SRZN transaction Derivative

Series C Common Stock Warrant (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -5,712
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 24 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,712
Exercise price: $16.00
Footnotes: F4, F5

SRZN transaction Derivative

Series D Common Stock Warrant (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -5,712
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 24 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,712
Exercise price: $16.00
Footnotes: F4, F6

SRZN transaction Derivative

Series A Common Stock Warrant (right to buy)

Award

Transaction value: $0
Shares: +1,474
Change %
Price: $0.000000
Shares after: 1,474
Date: 24 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,474
Exercise price: $12.45
Footnotes: F1

SRZN transaction Derivative

Series B Common Stock Warrant (right to buy)

Award

Transaction value: $0
Shares: +1,603
Change %
Price: $0.000000
Shares after: 1,603
Date: 24 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,603
Exercise price: $12.45
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The warrant was repriced pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025 to decrease the per share exercise price of the warrant from $16.96 to $12.45.

Footnote F2

The warrant was repriced pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025 to decrease the per share exercise price of the warrant from $15.71 to $12.45.

Footnote F3

The warrant expires on the fifth trading day following the occurrence of the Series B Milestone Event (as defined in the Series B Common Stock Warrant). In the event the Series B Milestone Event has not occurred prior to the fifth anniversary of the issuance date of the warrant, the warrant will automatically terminate on such anniversary date.

Footnote F4

The warrant was cancelled pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025.

Footnote F5

The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series C Milestone Event (as defined in the Series C Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series C Common Stock Warrant).

Footnote F6

The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series D Milestone Event (as defined in the Series D Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series D Common Stock Warrant).